ClinicalTrials.gg
RecruitingNCT06954714LARGER-DCBUpdated Oct 22, 2026

Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions

An interventional study of Drug-eluting stent implantation and Drug-coated balloon angioplasty in Coronary Artery Disease, sponsored by Chonnam National University Hospital. Recruiting at 8 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 22, 20268 sites added8 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 361 studies in Coronary Artery Disease with a site in Korea, Republic of — 81 open to participants now, 103 under way, 2 of them phase 3. Coronary Artery Disease · Korea, Republic of.

Planned enrollment
132nd of 208
256 · median 472
Started
2025
with 9 others
No phase
91 of 361
32 open now
Primary completion
2027-12
later than 51 of 102 live
Registered
339th of 361
by date

Among the 361 studies in Coronary Artery Disease with a site in Korea, Republic of, this one is the 132nd largest by planned enrollment of the 208 interventional ones that give a count, is one of 10 that started in 2025, is one of 91 with no phase, reaches primary completion later than 51 of the 102 other live ones, and was the 339th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

81 of the 361 studies in Coronary Artery Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

75 more — sign in →

All 81 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 361 studies in Coronary Artery Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study aims to compare late-lumen loss (LLL) between DCB and DES to treat de novo coronary artery stenosis by intravascular ultrasound (IVUS).

Read the detailed description

Drug-eluting stent (DES) is the standard of care for patients with coronary artery disease who are eligible for percutaneous coronary intervention (PCI).1 During long-term follow-up, remained metallic stent strut continuously related with stent-related cardiovascular events.2 As an alternative option to DES, drug-coated balloon (DCB) which has benefit of having shorter DAPT maintenance duration due to the absence of metallic scaffolds and polymers, has been introduced. Based on meta-analysis based on many randomized clinical trials (RCT),3,4 its use has been established in in-stent restenosis of bare-metal stents and DES.5 Furthermore, recent RCTs demonstrated efficacy and safety of DCB in de novo coronary lesions in small vessels with reference vessel size \<3.0mm.6,7 For the patients with de novo, non-complex coronary artery lesions, REC-CAGEFREE I tested the non-inferiority of DCB angioplasty with DES implantation, irrespective of vessel diameter.8 Overall, 2272 patients were randomly assigned to the DCB or the DES group. At 2 years, adverse events occurred in 6.4% of DCB group and 3.4% of DES group and failed to prove the non-inferiority of DCB angioplasty (P for non-inferiority=0.65). Regarding the heterogenous results, it is questionable that DCB angioplasty for large de novo lesions is safe and effective compared with DES implantation.

On this background, the current study aims to compare late-lumen loss (LLL) between DCB and DES to treat de novo coronary artery stenosis by intravascular ultrasound (IVUS).

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • drug-coated balloon
  • intravascular ultrasound
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be at least 19 years of age
  2. Subject who is able to understand risks, benefits and treatment alternatives and sign voluntarily
  3. Patients with at least one lesion with greater than 50% diameter stenosis or fractional flow reserve ≤0.80 requiring revascularization in de-novo coronary artery of reference vessel size ≥3.0 mm

Exclusion criteria

Exclusion Criteria

  1. Patients unable to provide consent
  2. Patients with known intolerance to aspirin, P2Y12 inhibitors, or components of drug-eluting stents
  3. Patients with angiographic findings of 1) Left main coronary artery disease 2) In-stent restenosis is the cause of target lesion 3) Target lesion in bypass graft 4) True bifurcation lesion that requires upfront 2-stenting
  4. Patients who have non-cardiac co-morbid conditions with \<1 year
  5. Patients who may result in protocol non-compliance (site investigator's medical judgment)
  6. Patients with cardiogenic shock or cardiac arrest
  7. Patients with severe left ventricular systolic dysfunction ( \<30%)
  8. Patients with severe valvular heart disease requiring open heart surgery
  9. Pregnant or lactating women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
256 participants (estimated)

Study arms

  • Active comparator
    Drug-eluting stent

    In DES group, latest second-generation DES will be used in accordance with standard practice guideline.

    Procedure: Drug-eluting stent implantation

  • Experimental
    Drug-coated balloon

    In DCB group, commercially available DCB (Agent, Boston Scientific, USA) will be used. DCB angioplasty will be recommended as follows to fully optimized procedural results. First, DCB size should be 1:1 ratio with reference vessel size. Second, delivery time of DCB should be within 30 seconds. Third, total inflation time of DCB will be recommended from 30 to 60 seconds.

    Procedure: Drug-coated balloon angioplasty

Interventions

  • ProcedureDrug-eluting stent implantation

    IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups. In DES group, latest second-generation DES will be used in accordance with standard practice guideline.

  • ProcedureDrug-coated balloon angioplasty

    IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups. In DCB group, commercially available DCB (Agent, Boston Scientific, USA) will be used. DCB angioplasty will be recommended as follows to fully optimized procedural results. First, DCB size should be 1:1 ratio with reference vessel size. Second, delivery time of DCB should be within 30 seconds. Third, total inflation time of DCB will be recommended from 30 to 60 seconds.

06

What researchers measure

Primary outcomes

  1. Late-lumen loss

    Mean difference of late-lumen loss between DCB and DES in IVUS

    Time frame: 9 months after last patient enrollment

Secondary outcomes

  1. Minimal lumen diameter in QCA

    Mean difference of minimal lumen diameter in QCA

    Time frame: 9 months after last patient enrollment

  2. % diameter stenosis in QCA

    Mean difference of % diameter stenosis in QCA

    Time frame: 9 months after last patient enrollment

  3. Minimal lumen diameter in IVUS

    Mean difference of minimal lumen diameter in IVUS

    Time frame: 9 months after last patient enrollment

  4. Cardiovascular death

    Cardiovascular death

    Time frame: 1 year after last patient enrollment

  5. All-cause death

    All-cause death

    Time frame: 1 year after last patient enrollment

  6. Rate of target vessel-MI

    Target vessel-MI

    Time frame: 1 year after last patient enrollment

  7. Rate of non-fatal MI

    Non-fatal MI

    Time frame: 1 year after last patient enrollment

  8. Rate of target lesion revascularization

    Clinically indicated target lesion revascularization

    Time frame: 1 year after last patient enrollment

  9. Rate of target vessel revascularization

    Clinically indicated target vessel revascularization

    Time frame: 1 year after last patient enrollment

  10. Rate of any revascularization

    Any revascularization

    Time frame: 1 year after last patient enrollment

  11. Rate of vessel or stent thrombosis

    Definite or probable thrombosis

    Time frame: 1 year after last patient enrollment

  12. Cardiovascular death or target vessel-related myocardial infarction

    A composite of cardiovascular death or target vessel-related myocardial infarction

    Time frame: 1 year after last patient enrollment

  13. All-cause death or non-fatal MI

    A composite of all-cause death or non-fatal myocardial infarction

    Time frame: 1 year after last patient enrollment

  14. Target vessel failure

    A composite of cardiovascular death, target-vessel myocardial infarction, and clinically indicated target vessel revascularization

    Time frame: 1 year after last patient enrollment

  15. Target lesion failure

    A composite of cardiovascular death, target-vessel myocardial infarction, and clinically indicated target lesion revascularization

    Time frame: 1 year after last patient enrollment

  16. Cardiovascular death, target-vessel MI, or vessel or stent thrombosis

    A composite of cardiovascular death, target-vessel MI, or vessel or stent thrombosis

    Time frame: 1 year after last patient enrollment

  17. All-cause death, non-fatal myocardial infarction, or target vessel revascularization

    A composite of all-cause death, non-fatal myocardial infarction, or target vessel revascularization

    Time frame: 1 year after last patient enrollment

  18. BARC type 2, 3, or 5 bleeding

    BARC type 2, 3, or 5 bleeding

    Time frame: 1 year after last patient enrollment

  19. Cerebrovascular accident

    Ischemic stroke, hemorrhagic stroke, or transient ischemic attack

    Time frame: 1 year after last patient enrollment

07

Study locations

1 of 8 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Yes After publication of main paper, de-identified data will be shared upon reasonable requests after discussion by Executive Committee.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After publication of main paper.

Access criteria: Executive Committee will discuss to share the de-identified data upon reasonable requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 28 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 2, 2025
StartActual
Aug 18, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 8 sites removed
Show 8 added (8 South Korea)
  • Kosin University Gospel Hospital · Busan, South Korea
  • Keimyung University Dongsan Hospital · Daegu, South Korea
  • Chonnam National University · Gwangju, South Korea
  • Jeonbuk National University Hospital · Jeonju, South Korea
  • Samsung Medical Center · Seoul, South Korea
  • Ewha Womans University Mokdong Hospital · Seoul, South Korea
  • Korea University Guro Hospital · Seoul, South Korea
  • Ulsan University Hospital · Ulsan, South Korea
Show 8 removed
  • Kosin University Gospel Hospital · Busan, South Korea
  • Keimyung University Dongsan Hospital · Daegu, South Korea
  • Chonnam National University · Gwangju, South Korea
  • Jeonbuk National University Hospital · Jeonju, South Korea
  • Samsung Medical Center · Seoul, South Korea
  • Ewha Womans University Mokdong Hospital · Seoul, South Korea
  • Korea University Guro Hospital · Seoul, South Korea
  • Ulsan University Hospital · Ulsan, South Korea
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    8 sites added, 8 sites removed
    Show 8 added (8 South Korea)
    • Kosin University Gospel Hospital · Busan, South Korea
    • Keimyung University Dongsan Hospital · Daegu, South Korea
    • Chonnam National University · Gwangju, South Korea
    • Jeonbuk National University Hospital · Jeonju, South Korea
    • Samsung Medical Center · Seoul, South Korea
    • Ewha Womans University Mokdong Hospital · Seoul, South Korea
    • Korea University Guro Hospital · Seoul, South Korea
    • Ulsan University Hospital · Ulsan, South Korea
    Show 8 removed
    • Kosin University Gospel Hospital · Busan, South Korea
    • Keimyung University Dongsan Hospital · Daegu, South Korea
    • Chonnam National University · Gwangju, South Korea
    • Jeonbuk National University Hospital · Jeonju, South Korea
    • Samsung Medical Center · Seoul, South Korea
    • Ewha Womans University Mokdong Hospital · Seoul, South Korea
    • Korea University Guro Hospital · Seoul, South Korea
    • Ulsan University Hospital · Ulsan, South Korea
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06954714
Lead sponsor
Chonnam National University Hospital
Responsible party
Young Joon Hong (Professor, Chonnam National University Hospital) — Principal investigator
First posted
May 2, 2025
Start date
Aug 18, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Seung Hun Lee, MD, PhD
Contact
lsh8602@naver.com
+82-62-220-6246
Joon Ho Ahn, MD, PhD
Contact
yhbky@naver.com
+82-62-220-5778
Young Joon Hong, MD, PhD
study chair · Chonnam National University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion